Comprehensive profiling of phosphate-containing compounds (PCCs) in untargeted metabolomics remains challenging due to their high hydrophilicity, poor separation, and low stability, which hampers high-throughput screening from large-scale liquid chromatography−mass spectrometry (LC−MS) datasets. Herein, an LC-MS-based chlorine-tagging strategy integrated with a Chlorine Signature Query Engine (Cl-SQE) was established for the rapid identification of potential PCCs in complex matrices. The novel derivatization reagent, [5-(2-chlorophenyl)isoxazol-3-yl]methyl amine (ClXIMA), can react with phosphate groups on PCCs, such as nucleotides, sugar phosphates, glycerophosphates, and nucleotide sugars under mild conditions, thereby markedly enhancing reversed-phase retention and separation resolution. More importantly, the incorporation of chlorine, identifiable by its characteristic isotopic peak pattern, provides a unique digital signature in the mass spectra. Leveraging these features, Cl-SQE, a data mining program, was developed to systematically and automatically extract candidate PCCs from large-scale datasets. By applying this strategy to liver tissues from a mouse model of cholestasis, 318 potential ClXIMA derivatives were screened out, and 189 metabolites were identified or tentatively assigned. Statistical analysis revealed significant disturbances in nucleotide metabolism, addressing a critical gap in phospho-metabolomic profiling for cholestatic disease and revealing dysregulated nucleotide homeostasis as a potential feature of cholestasis-associated metabolic remodeling. Overall, this platform facilitates the discovery of PCCs in complex matrices and provides new insights into the pathogenesis of cholestasis and other clinical diseases.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: